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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
01/09/2020 Oxygen 
targets in 
the 
intensive 
care unit 
during 
mechanical 
ventilation 
for acute 
respiratory 
distress 
syndrome: 
a rapid 
review 
Cochrane 
Systematic 
Review 
• An up-to-date 
understanding of how 
oxygen therapy should be 
targeted in adults with 
acute respiratory distress 
syndrome (ARDS), 
including ARDS secondary 
to viral illness such as 
COVID-19, and requiring 
mechanical ventilation in 
ICU 
• It is very uncertain whether 
a higher or lower oxygen 
target is more beneficial in 
patients with ARDS and 
receiving mechanical 
ventilation in ICU 
• Only one RCT was 
identified with a total of 205 
participants with a possible 
high risk of bias 
• Further well-conducted 
studies are needed to 
increase the certainty of 
findings  
Oxygen, 
ventilation, 
ICU 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
03/09/2020 Revealing 
the extent 
of the 
COVID-19 
pandemic 
in Kenya 
based on 
serological 
and PCR-
test data 
medRxiv pre-
print (not 
peer-
reviewed) 
• Using national surveillance 
PCR test, serological survey 
and mobility data, authors 
develop and fit a county-
specific transmission model for 
Kenya 
• It is estimated that the SARS-
CoV-2 pandemic peaked 
before the end of July 2020 in 
the major urban counties, with 
34-41% of residents infected 
and will peak elsewhere in the 
country within 2-3 months.  
• Analysis suggests the C19 
disease burden in Kenya may 
be far less than initially feared 
• A similar scenario across SSA 
would have implications for 
balancing the consequences of 
restrictions with those of C19 
Kenya, 
infection 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
30/08/2020 Transmission 
risk of 
respiratory 
viruses in 
natural and 
mechanical 
ventilation 
environments: 
implications 
for SARS-
CoV-2 
transmission 
in Africa 
BMJ Global 
Health | 
Analysis 
• SARS-CoV-2 can 
become aerosolised 
during medical 
procedures and 
malfunctioning air 
conditioners 
• Most resource-limited 
healthcare settings lack 
air handling systems to 
filter infectious 
contaminants in the air 
• A hybrid approach of 
using natural 
ventilation coupled with 
affordable mechanical 
ventilation devices 
could prove useful in 
controlling infection 
transmission in LMIC 
Transmission, 
medical 
procedures 
02/09/2020 Coronavirus 
(COVID-19): 
infection 
control and 
prevention 
measures 
Cochrane 
Special 
Collections | 
updated 
• Updated to include 
Rapid, point-of-care 
antigen and molecular-
based tests for 
diagnosis of SARS-
CoV-2 infection 
IPC 
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
28/08/2020 Salivary 
detection 
of 
COVID-
19 
Annals of 
Internal 
Medicine | 
Letter 
• The detection rate of SARS-CoV-
2 using a novel, self-administered 
kit for saliva collection was less 
when compared with standard 
swab testing among patients who 
were asymptomatic but at high 
risk or who were mildly 
symptomatic 
• This study does show the 
feasibility of a simple, safe 
collection tool for salivary 
detection of SARS-CoV-2 in the 
setting of a COVID-19 testing 
centre 
Saliva, 
testing 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
02.09.2020 Association 
between 
administration 
of systemic 
corticosteroids 
and mortality 
among critically 
ill patients with 
COVDI-19: a 
meta-analysis 
JAMA | Meta-
analysis 
• The WHO rapid 
evidence appraisal 
for COVID-19 
therapies (REACT) 
working group 
• Prospective meta-
analysis of 7 
randomised trials 
that included 1703 
patients of whom 
647 died 
• Systemic 
corticosteroids 
reduced the risk of 
dying from severe 
C19 at 28 days by 
one-third 
corticosteroids 
02.09.2020 Effect of 
hydrocortisone 
on mortality and 
organ support in 
patients with 
severe COVID-
19: the REMAP-
CAP Covid-19 
corticosteroid 
domain 
randomized 
clinical trial 
JAMA | 
Original 
Investigation 
• An ongoing adaptive 
platform trial testing 
multiple 
interventions within 
multiple therapeutic 
domains 
• Randomised to 
receive a fixed 7-day 
course of 
intravenous 
hydrocortisone (50 
mg or 100 mg every 
6 hours), a shock-
dependent course 
(50 mg every 6 
hours when shock 
was clinically 
evident), or no 
hydrocortisone 
• In patients with 
severe C19, 
treatment with a 7-
day fixed-dose 
course of 
hydrocortisone or 
shock-dependent 
dosing of 
hydrocortisone, 
compared with no 
hydrocortisone, 
resulted in 93% and 
80% probabilities of 
superiority with 
regard to the odds of 
improvement in 
organ support-free 
days within 21 days 
• Note that the trial 
was stopped early 
and no treatment 
strategy met 
prespecified criteria 
for statistical 
superiority, 
precluding definitive 
conclusions 
hydrocortisone 
02.09.2020 Effect of 
dexamethasone 
on days alive 
and ventilator-
free in patients 
with acute 
respiratory 
distress 
JAMA | 
Original 
Investigation 
• Multicentre, 
randomised, open-
label, clinical trial 
conduced in 41 
intensive care units 
in Brazil 
• Intended to recruit a 
sample size of 350 
patients but the trial 
was stopped early 
dexamethasone 
syndrome and 
COVID-19: the 
CoDEX 
randomized 
clinical trial 
following publication 
of a related study 
• Randomised to 
receive 20mg 
dexamethasone 
intravenously daily 
for 5 days, 10mg 
dexamethasone 
daily for 5 days or 
until ICU discharge, 
plus standard of care 
or standard care 
alone 
• Among patients with 
C19 and moderate 
or severe acute 
respiratory distress 
syndrome (ARDS), 
use of intravenous 
dexamethasone plus 
standard of care 
compared with 
standard care along 
resulted in a 
significant increase 
in the number of 
ventilator-free days 
over 28 days 
02.09.2020 Effect of 
hydrocortisone 
on 21-day 
mortality or 
respiratory 
support among 
critically ill 
patients with 
COVID-19 
JAMA | 
Original 
Investigation 
• Multicentre 
randomised double-
blind sequential trial 
in France 
• Interim analyses 
planned every 50 
patients with the 
intention to enrol 290 
patients but was 
stopped early (after 
149 patients) 
following the 
recommendation of 
the DSMB 
• Randomised to 
receive low-dose 
hydrocortisone or 
placebo 
• In this study of 
critically ill patients 
with C19 and acute 
respiratory failure, 
low-dose 
hydrocortisone, 
compared with 
placebo, did not 
significantly reduce 
treatment failure 
hydrocortisone 
(defined as death or 
persistent respiratory 
support) at day 21 
• Note though that this 
study was stopped 
early and was likely 
underpowered to 
find a statistically 
and clinically 
importance 
difference in the 
primary outcome 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
 02/09/2020 Phase 1-2 
trial of a 
SARS-CoV-2 
recombinant 
spike protein 
nanoparticle 
vaccine 
NEJM | Article 
• Randomised, placebo-
controlled, phase 1-2 
trial of the SARS-CoV-2 
recombinant spike 
protein nanoparticle 
vaccine 
• At 35 days, NVX-
CoV2373 appeared to 
be safe, and elicited 
immune responses that 
exceeded levels in C19 
convalescent serum 
• The Matrix-M1 adjuvant 
induced CD4+ T cell 
responses that were 
biased toward the Th1 
phenotype 
Phase 1-2 
trial, 
recombinant 
vaccine 
  
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
Sept 2020 Will the COVID-19 pandemic threaten the 
SDGs? 
The Lancet Public Health | 
Editorial 
03/09/2020 Panelists named to join the Independent 
Panel for Pandemic Preparedness and 
Response 
Independent Panel for Pandemic 
Preparedness and Response | 
News 
02/09/2020 Corticosteroids in COVID-19 ARDs: 
Evidence and Hope During the Pandemic 
JAMA | Editorial 
01/09/2020 Asymptomatic SARS-CoV-2 infection: the tip 
or the iceberg? 
Thorax | Commentary 
01/09/2020 Long-term consequences of COVID-19: 
research needs 
The Lancet Infectious Diseases | 
Comment 
01/09/2020 Towards health market systems changes for 
migrant workers based on the COVID-19 
experience in Singapore 
BMJ Global Health | 
Commentary 
29/08/2020 Bangladesh’s COVID-19 testing criticised The Lancet | World Report 
28/08/2020 Mental health and the COVID-19 pandemic” 
what we knew, what we now know, and what 
we still don’t know 
CGD | Blog 
27/08/2020 COVID-19 vaccine trials should seek 
worthwhile efficacy 
The Lancet | Comment 
  
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
02.09.2020 Corticosteroids for 
COVID-19 
WHO | 
Living 
Guidance 
• The guideline panel’s 
recommendations were supported 
by published meta-analyses and 
randomised controlled trials and 
considerations of an individual 
patient perspective and contextual 
factors for countries and health 
care systems 
• There are two recommendations: 
(1) a strong recommendation for 
systemic (intravenous or oral) 
corticosteroid therapy (e.g. 6 mg of 
dexamethasone orally or iv daily or 
50 mg of hydrocortisone 
intravenously every 8 hours) for 7 
to 10 days in patients with severe 
and critical C19 and (2) a 
conditional recommendation not to 
use corticosteroid therapy in 
patients with non-severe C19  
• A panel warning that indiscriminate 
use of any therapy for C19 would 
potentially rapidly deplete global 
resources and deprive patients who 
may benefit from it most as 
potentially life-saving therapy 
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Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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C19 Resource Hubs 
Global  Regional & 
Country 
Academic 
journals & 
Publishers 
Institutes/Centres
/Funders/Other 
Health 
Topics 
Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communication 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of 
the WHO 
ICL MRC Centre 
for Global 
Infectious 
Disease Analysis 
Global 
Menstrual 
Collective  
  Disability 
and inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashin
g in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Development 
Direct C19 
blog series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and Eastern 
Africa 
Health 
Policy and 
Planning  
Norwegian 
Institute of Public 
Health 
    
COVID-19 
Digest 
UNHCR  South 
African 
Government 
JAMA 
Network 
Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetMap 
Team 
  Wiley       
Global 
Partnership for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global Impact 
Study 
    
  
GISAID           
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online 
courses 
Varies WHO 
Available 
now 
Standard precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
FutureLearn 
LSHTM/UK PHRST 
weekly 
study 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 Diagnostics 
and Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. 
Except where otherwise stated, it is licensed for non-commercial purposes under the 
terms of the Open Government Licence v3.0. K4D cannot be held responsible for errors, 
omissions or any consequences arising from the use of information contained in this 
health evidence summary. Any views and opinions expressed do not necessarily reflect 
those of FCDO, K4D or any other contributing organisation.  
© Crown copyright 2020. 
  
 
 
